The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?

References

• Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol. 2010;28:445–489.
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145–173.
   PubMed Web of Science ®Google Scholar
• Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007 Feb;13(2):139–145.
   PubMed Web of Science ®Google Scholar
• Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol. 2008 May;8(5):337–348.
   PubMed Web of Science ®Google Scholar
• Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006 Sep 22;126(6):1121–1133.
   PubMed Web of Science ®Google Scholar
• Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005 Jan 17;201(2):233–240.
   PubMed Web of Science ®Google Scholar
• Chen Y, Langrish CL, McKenzie B, et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest. 2006 May;116(5):1317–1326.
   PubMed Web of Science ®Google Scholar
• Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010 Mar;129(3):311–321.
   PubMed Web of Science ®Google Scholar
• Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol. 2007 Jun;8(6):639–646.
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000 Nov;13(5):715–725.
   PubMed Web of Science ®Google Scholar
• Duvallet E, Semerano L, Assier E, et al. Interleukin-23: a key cytokine in inflammatory diseases. Ann Med. 2011 Nov;43(7):503–511.
   PubMed Web of Science ®Google Scholar
• Langowski JL, Kastelein RA, Oft M. Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol. 2007 May;28(5):207–212.
   PubMed Web of Science ®Google Scholar
• Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature. 2006 Jul 27;442(7101):461–465.
   PubMed Web of Science ®Google Scholar
• Hu J, Yuan X, Belladonna ML, et al. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res. 2006 Sep 1;66(17):8887–8896.
   PubMed Web of Science ®Google Scholar
• Chen Z, Laurence A, O’Shea JJ. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin Immunol. 2007 Dec;19(6):400–408.
   PubMed Web of Science ®Google Scholar
• Volpe E, Servant N, Zollinger R, et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol. 2008 Jun;9(6):650–657.
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest. 2006 May;116(5):1218–1222.
   PubMed Web of Science ®Google Scholar
• Cho JH, Weaver CT. The genetics of inflammatory bowel disease. Gastroenterology. 2007 Oct;133(4):1327–1339.
   PubMed Web of Science ®Google Scholar
• Stark MA, Huo Y, Burcin TL, et al. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity. 2005 Mar;22(3):285–294.
   PubMed Web of Science ®Google Scholar
• Tonel G, Conrad C, Laggner U, et al. Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol. 2010 Nov 15;185(10):5688–5691.
   PubMed Web of Science ®Google Scholar
• Le Gouvello S, Bastuji-Garin S, Aloulou N, et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut. 2008 Jun;57(6):772–779.
   PubMed Web of Science ®Google Scholar
• Bailey SR, Nelson MH, Himes RA, et al. Th17 cells in cancer: the ultimate identity crisis. Front Immunol. 2014;5:276.
   PubMed Web of Science ®Google Scholar
• Wang L, Yi T, Kortylewski M, et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009 Jul 6;206(7):1457–1464.
   PubMed Web of Science ®Google Scholar
• Lanca T, Silva-Santos B. The split nature of tumor-infiltrating leukocytes: implications for cancer surveillance and immunotherapy. Oncoimmunology. 2012 Aug 1;1(5):717–725.
   PubMed Web of Science ®Google Scholar
• Marsh JL, Jackman CP, Tang SN, et al. Embelin suppresses pancreatic cancer growth by modulating tumor immune microenvironment. Front Biosci (Landmark Ed). 2014;19:113–125.
   PubMed Web of Science ®Google Scholar
• Chang SH, Mirabolfathinejad SG, Katta H, et al. T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5664–5669.
   PubMed Web of Science ®Google Scholar
• Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009 Aug 6;114(6):1141–1149.
   PubMed Web of Science ®Google Scholar
• Munn DH. Th17 cells in ovarian cancer. Blood. 2009 Aug 6;114(6):1134–1135.
   PubMed Web of Science ®Google Scholar
• Baird AM, Leonard J, Naicker KM, et al. IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer. Lung Cancer. 2013 Jan;79(1):83–90.
   PubMed Web of Science ®Google Scholar
• Charles KA, Kulbe H, Soper R, et al. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest. 2009 Oct;119(10):3011–3023.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang L, Zhang J, et al. Interleukin 23 regulates proliferation of lung cancer cells in a concentration-dependent way in association with the interleukin-23 receptor. Carcinogenesis. 2013 Mar;34(3):658–666.
   PubMed Web of Science ®Google Scholar
• Lan F, Zhang L, Wu J, et al. IL-23/IL-23R: potential mediator of intestinal tumor progression from adenomatous polyps to colorectal carcinoma. Int J Colorectal Dis. 2011 Dec;26(12):1511–1518.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Ogawa H, Miura K, et al. IL-23 directly enhances the proliferative and invasive activities of colorectal carcinoma. Oncol Lett. 2012 Aug;4(2):199–204.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013 Apr;49(6):1374–1403.
   PubMed Web of Science ®Google Scholar
• Zheng J, Jiang L, Zhang L, et al. Functional genetic variations in the IL-23 receptor gene are associated with risk of breast, lung and nasopharyngeal cancer in Chinese populations. Carcinogenesis. 2012 Dec;33(12):2409–2416.
   PubMed Web of Science ®Google Scholar
• O’Callaghan DS, O’Donnell D, O’Connell F, et al. The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol. 2010 Dec;5(12):2024–2036.
   PubMed Web of Science ®Google Scholar
• Lawless MW, Norris S, O’Byrne KJ, et al. Targeting histone deacetylases for the treatment of disease. J Cell Mol Med. 2009 May;13(5):826–852.
   PubMed Web of Science ®Google Scholar
• Lawless MW, O’Byrne KJ, Gray SG. Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy. J Cell Mol Med. 2009 Sep;13(9A):2800–2821.
   PubMed Web of Science ®Google Scholar
• O’Byrne KJ, Barr MP, Gray SG. The role of epigenetics in resistance to Cisplatin chemotherapy in lung cancer. Cancers (Basel). 2011;3(1):1426–1453.
   PubMedGoogle Scholar
• Romagnani S, Maggi E, Liotta F, et al. Properties and origin of human Th17 cells. Mol Immunol. 2009 Nov;47(1):3–7.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Iizasa T, Nakajima T, et al. Aberrant methylation of IL-12Rbeta2 gene in lung adenocarcinoma cells is associated with unfavorable prognosis. Ann Surg Oncol. 2007 Sep;14(9):2636–2642.
   PubMed Web of Science ®Google Scholar
• Baird AM, Gray SG, O’Byrne KJ. IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF. Eur J Cancer. 2011 Aug;47(12):1908–1918.
   PubMed Web of Science ®Google Scholar
• Guillon A, Gueugnon F, Mavridis K, et al. Interleukin-22 receptor is overexpressed in nonsmall cell lung cancer and portends a poor prognosis. Eur Respir J. 2016 Apr;47(4):1277–1280.
   PubMedGoogle Scholar
• Tekpli X, Landvik NE, Anmarkud KH, et al. DNA methylation at promoter regions of interleukin 1B, interleukin 6, and interleukin 8 in non-small cell lung cancer. Cancer Immunol Immunother. 2013 Feb;62(2):337–345.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang Y, Yang XO, et al. Transcription of Il17 and Il17f is controlled by conserved noncoding sequence 2. Immunity. 2012 Jan 27;36(1):23–31.
   PubMed Web of Science ®Google Scholar
• Thomas RM, Sai H, Wells AD. Conserved intergenic elements and DNA methylation cooperate to regulate transcription at the il17 locus. J Biol Chem. 2012 Jul 20;287(30):25049–25059.
   PubMed Web of Science ®Google Scholar
• Li Q, Zou J, Wang M, et al. Critical role of histone demethylase Jmjd3 in the regulation of CD4+ T-cell differentiation. Nat Commun. 2014;5:5780.
   PubMed Web of Science ®Google Scholar
• Liu Z, Cao W, Xu L, et al. The histone H3 lysine-27 demethylase Jmjd3 plays a critical role in specific regulation of Th17 cell differentiation. J Mol Cell Biol. 2015 Dec;7(6):505–516.
   PubMed Web of Science ®Google Scholar
• Ma J, Wang N, Zhang Y, et al. KDM6B elicits cell apoptosis by promoting nuclear translocation of FOXO1 in non-small cell lung cancer. Cell Physiol Biochem. 2015;37(1):201–213.
   PubMed Web of Science ®Google Scholar
• Tian C, Deng H, Tang X, et al. Effect of Jumonji domain-containing protein-3 on the proliferation and migration of lung cancer cell line. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2012 Jun;29(3):514–518.
   PubMedGoogle Scholar
• Numasaki M, Watanabe M, Suzuki T, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol. 2005 Nov 1;175(9):6177–6189.
   PubMed Web of Science ®Google Scholar
• Wei L, Wang H, Yang F, et al. Interleukin-17 potently increases non-small cell lung cancer growth. Mol Med Rep. 2016 Feb;13(2):1673–1680.
   PubMed Web of Science ®Google Scholar
• Xu B, Guenther JF, Pociask DA, et al. Promotion of lung tumor growth by interleukin-17. Am J Physiol Lung Cell Mol Physiol. 2014 Sep 15;307(6):L497–508.
   PubMed Web of Science ®Google Scholar
• Lin Q, Xue L, Tian T, et al. Prognostic value of serum IL-17 and VEGF levels in small cell lung cancer. Int J Biol Markers. 2015;30(4):e359–e363.
   PubMed Web of Science ®Google Scholar
• Li Y, Cao ZY, Sun B, et al. Effects of IL-17A on the occurrence of lung adenocarcinoma. Cancer Biol Ther. 2011 Oct 1;12(7):610–616.
   PubMed Web of Science ®Google Scholar
• Xu C, Hao K, Yu L, et al. Serum interleukin-17 as a diagnostic and prognostic marker for non-small cell lung cancer. Biomarkers. 2014 Jun;19(4):287–290.
   PubMed Web of Science ®Google Scholar
• Pan B, Che D, Cao J, et al. Interleukin-17 levels correlate with poor prognosis and vascular endothelial growth factor concentration in the serum of patients with non-small cell lung cancer. Biomarkers. 2015;20(4):232–239.
   PubMed Web of Science ®Google Scholar
• Pan B, Shen J, Cao J, et al. Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer. Sci Rep. 2015;5:16053.
   PubMed Web of Science ®Google Scholar
• Reppert S, Boross I, Koslowski M, et al. A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer. Nat Commun. 2011;2:600.
   PubMed Web of Science ®Google Scholar
• Huang Q, Fan J, Qian X, et al. Retinoic acid-related orphan receptor C isoform 2 expression and its prognostic significance for non-small cell lung cancer. J Cancer Res Clin Oncol. 2016 Jan;142(1):263–272.
   PubMed Web of Science ®Google Scholar
• Li S, Li Y, Qu X, et al. Detection and significance of TregFoxP3(+) and Th17 cells in peripheral blood of non-small cell lung cancer patients. Arch Med Sci. 2014 May 12;10(2):232–239.
   PubMed Web of Science ®Google Scholar
• Duan MC, Han W, Jin PW, et al. Disturbed Th17/Treg balance in patients with non-small cell lung cancer. Inflammation. 2015 Dec;38(6):2156–2165.
   PubMed Web of Science ®Google Scholar
• Huang Q, Du J, Fan J, et al. The effect of proinflammatory cytokines on IL-17RA expression in NSCLC. Med Oncol. 2014 Sep;31(9):144.
   PubMed Web of Science ®Google Scholar
• Zhang P, Sun Y, Ma L. ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle. 2015;14(4):481–487.
   PubMed Web of Science ®Google Scholar
• Gu K, Li MM, Shen J, et al. Interleukin-17-induced EMT promotes lung cancer cell migration and invasion via NF-kappaB/ZEB1 signal pathway. Am J Cancer Res. 2015;5(3):1169–1179.
   PubMed Web of Science ®Google Scholar
• Baird AM, Dockry E, Daly A, et al. IL-23R is epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer. Front Oncol. 2013;3:162.
   PubMedGoogle Scholar
• Sabat R, Ouyang W, Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov. 2014 Jan;13(1):21–38.
   PubMed Web of Science ®Google Scholar
• Ye ZJ, Zhou Q, Yin W, et al. Interleukin 22-producing CD4+ T cells in malignant pleural effusion. Cancer Lett. 2012 Dec 29;326(1):23–32.
   PubMed Web of Science ®Google Scholar
• Zhang W, Chen Y, Wei H, et al. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res. 2008 Oct 15;14(20):6432–6439.
   PubMed Web of Science ®Google Scholar
• Kobold S, Volk S, Clauditz T, et al. Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells. J Thorac Oncol. 2013 Aug;8(8):1032–1042.
   PubMed Web of Science ®Google Scholar
• Liao C, Yu ZB, Meng G, et al. Association between Th17-related cytokines and risk of non-small cell lung cancer among patients with or without chronic obstructive pulmonary disease. Cancer. 2015 Sep 1;121(Suppl 17):3122–3129.
   PubMed Web of Science ®Google Scholar
• Liu F, Pan X, Zhou L, et al. Genetic polymorphisms and plasma levels of interleukin-22 contribute to the development of nonsmall cell lung cancer. DNA Cell Biol. 2014 Oct;33(10):705–714.
   PubMed Web of Science ®Google Scholar
• Bi Y, Cao J, Jin S, et al. Interleukin-22 promotes lung cancer cell proliferation and migration via the IL-22R1/STAT3 and IL-22R1/AKT signaling pathways. Mol Cell Biochem. 2016 Apr;415(1–2):1–11.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Ruby CE, Hughes T, et al. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer. 2014;2:11.
   PubMedGoogle Scholar
• Chen L, He Z, Slinger E, et al. IL-23 activates innate lymphoid cells to promote neonatal intestinal pathology. Mucosal Immunol. 2015 Mar;8(2):390–402.
   PubMed Web of Science ®Google Scholar
• McGeachy MJ. GM-CSF: the secret weapon in the T(H)17 arsenal. Nat Immunol. 2011 Jun;12(6):521–522.
   PubMed Web of Science ®Google Scholar
• Noster R, Riedel R, Mashreghi MF, et al. IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells. Sci Transl Med. 2014 Jun 18;6(241):241ra80.
   PubMed Web of Science ®Google Scholar
• Katsumata N, Eguchi K, Fukuda M, et al. Serum levels of cytokines in patients with untreated primary lung cancer. Clin Cancer Res. 1996 Mar;2(3):553–559.
   PubMed Web of Science ®Google Scholar
• Tsuruta N, Yatsunami J, Takayama K, et al. Granulocyte-macrophage-colony stimulating factor stimulates tumor invasiveness in squamous cell lung carcinoma. Cancer. 1998 Jun 1;82(11):2173–2183.
   PubMed Web of Science ®Google Scholar
• Oshika Y, Nakamura M, Abe Y, et al. Growth stimulation of non-small cell lung cancer xenografts by granulocyte-macrophage colony-stimulating factor (GM-CSF). Eur J Cancer. 1998 Nov;34(12):1958–1961.
   PubMed Web of Science ®Google Scholar
• Grossi F, Tiseo M. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC). Crit Rev Oncol Hematol. 2006 Jun;58(3):221–230.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Saito S, Kamamura Y, et al. Granulocyte/macrophage-colony-stimulating factor augments lymphokine-activated killer activity from lymphocytes via macrophages in lung cancer patients. Cancer Immunol Immunother. 2000 Dec;49(10):537–543.
   PubMed Web of Science ®Google Scholar
• Chan B, Lee W, Hu CX, et al. Adoptive cellular immunotherapy for non-small cell lung cancer: a pilot study. Cytotherapy. 2003;5(1):46–54.
   PubMed Web of Science ®Google Scholar
• Salgia R, Lynch T, Skarin A, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003 Feb 15;21(4):624–630.
   PubMed Web of Science ®Google Scholar
• Nemunaitis J. GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer. J Control Release. 2003 Aug 28;91(1–2):225–231.
   PubMed Web of Science ®Google Scholar
• Tian H, Shi G, Yang G, et al. Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects. BMC Cancer. 2014;14:48.
   PubMed Web of Science ®Google Scholar
• Du T, Shi G, Li YM, et al. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers. Cancer Gene Ther. 2014 Aug;21(8):340–348.
   PubMed Web of Science ®Google Scholar
• van Nieuwenhuijze AE, van de Loo FA, Walgreen B, et al. Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-kappaB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis. Arthritis Res Ther. 2015;17:163.
   PubMed Web of Science ®Google Scholar
• Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2000 May 15;19(21):2468–2473.
   PubMed Web of Science ®Google Scholar
• Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006 May;116(5):1310–1316.
   PubMed Web of Science ®Google Scholar
• Yu Y, Zhao Q, Wang Z, et al. Activated STAT3 correlates with prognosis of non-small cell lung cancer and indicates new anticancer strategies. Cancer Chemother Pharmacol. 2015 May;75(5):917–922.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2014 Feb;73(2):349–356.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014 Jul 24;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015 Sep;73(3):400–409.
   PubMed Web of Science ®Google Scholar
• Xiong HZ, Gu JY, He ZG, et al. Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015;8(3):3156–3172.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. New England J Med. 2015;373(14):1318–1328.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014 Jun 12;370(24):2295–2306.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Niiro H, Ootaki K. Japanese brodalumab study group. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016;81(1):44–52.
   Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015 Aug 8;386(9993):541–551.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Greenwald M, Cho CS, et al. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2014 Jul;66(7):1693–1704.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Duffin KC, Bissonnette R, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015 Jul 9;373(2):136–144.
   PubMed Web of Science ®Google Scholar
• Papp K, Thaci D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930–939.
   PubMed Web of Science ®Google Scholar
• Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015 Jul;136(1):116–24e7.
   PubMed Web of Science ®Google Scholar
• Papp K, Menter A, Sofen H, et al. Efficacy and safety of different dose regimens of a selective IL-23p19 inhibitor (BI 655066) compared with ustekinumab in patients with moderate-to-severe plaque psoriasis with and without psoriatic arthritis. Arthritis Rheumatol. 2015 Oct;67(Abstract):2144.
   Google Scholar
• Reich K, Langley RG, Papp KA, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med. 2011 Oct 27;365(17):1586–1596.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Gottlieb AB, et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol. 2012 Feb;132(2):304–314.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008 May 17;371(9625):1665–1674.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008 May 17;371(9625):1675–1684.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Strober BE, Van De Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010 Jan 14;362(2):118–128.
   PubMed Web of Science ®Google Scholar
• Tsai TF, Ho JC, Song M, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011 Sep;63(3):154–163.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013 Aug 31;382(9894):780–789.
   PubMed Web of Science ®Google Scholar
• Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014 Jun;73(6):990–999.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014 Jun;73(6):1000–1006.
   PubMed Web of Science ®Google Scholar
• Sandborn W, Gasink C, Blank M, et al. O-001 A multicenter, double-blind, placebo-controlled phase3 study of ustekinumab, a human IL-12/23P40 mAB, in moderate-service crohn’s disease refractory to anti-TFNalpha: UNITI-1. Inflamm Bowel Dis. 2016 Mar;22(Suppl 1):S1.
   Google Scholar
• Krausz S, Boumans MJ, Gerlag DM, et al. Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum. 2012 Jun;64(6):1750–1755.
   PubMed Web of Science ®Google Scholar
• Sands BE, Jacobson EW, Sylwestrowicz T, et al. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn’s disease. Inflamm Bowel Dis. 2010 Jul;16(7):1209–1218.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013 Feb 9;381(9865):451–460.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012 Aug 9;367(6):495–507.
   PubMed Web of Science ®Google Scholar
• Kremer J, Li ZG, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013 Aug 20;159(4):253–261.
   PubMed Web of Science ®Google Scholar
• Van Der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013 Mar;65(3):559–570.
   PubMed Web of Science ®Google Scholar
• Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014 Jun 19;370(25):2377–2386.
   PubMed Web of Science ®Google Scholar
• Bachelez H, Van De Kerkhof PCM, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386(9993):552–561.
   PubMed Web of Science ®Google Scholar
• Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol. 2012 Oct;67(4):658–664.
   PubMed Web of Science ®Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015 Jul;73(1):37–49.
   PubMed Web of Science ®Google Scholar
• Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387–1399.
   Google Scholar
• Reich K, Soung J, Gooderham M Efficacy and safety of apremilast or etanercept compared with placebo in patients with moderate to severe psoriasis. Presented at the 73rd Annual Meeting of the American Academy of Dermatology; 2015 March 20–24; San Francisco.
   Google Scholar
• Souto A, Gomez-Reino JJ. Apremilast for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2015 Oct;26:1–10.
   Google Scholar
• Paller A, Wynnis T, Lebwohl MM, et al. Crisaborole topical ointment, 2%: A novel, nonsteroidal, topical antiinflammatory, phosphodiesterase 4 inhibitor: results from two phase 3 studies treating children and adult patients with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2016;74(5,Supplement 1):AB86.
   Google Scholar
• Furue M, Kitahara Y, Akama H, et al. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial. J Dermatol. 2014;41(7):577–585.
   PubMed Web of Science ®Google Scholar
• Ohba F, Matsuki S, Imayama S, et al. Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: an investigator-blinded, vehicle-controlled study. J Dermatolog Treat. 2016;14:1–6.
   Google Scholar
• Nemoto O, Hayashi N, Kitahara Y, et al. Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: results from a randomized, vehicle-controlled exploratory trial. J Dermatol. 2015 Dec 24. doi: 10.1111/1346-8138.13231. [Epub ahead of print].
   Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 Sep 19;386(9999):1137–1146.
   PubMed Web of Science ®Google Scholar
• Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013 Feb;168(2):402–411.
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012 Mar 29;366(13):1181–1189.
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012 Dec;61(12):1693–1700.
   PubMed Web of Science ®Google Scholar
• Rothstein B, Gottlieb A. Secukinumab for treating plaque psoriasis. Expert Opin Biol Ther. 2016;16(1):119–128.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012 Mar 29;366(13):1190–1199.
   PubMed Web of Science ®Google Scholar
• Vanheusden K, Detalle L, Hemeryck A, et al. Pre-clinical proof-of-concept of ALX-0761, a nanobody (R) neutralizing both IL-17A and F in a cynomolgus monkey collagen induced arthritis model. Arthritis Rheumatism. 2013;65:S543–S543.
   PubMed Web of Science ®Google Scholar
• Danesh MJ, Kimball AB. Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States. J Am Acad Dermatol. 2016 Jan;74(1):190–192.
   PubMed Web of Science ®Google Scholar
• Langley RG, Papp K, Gottlieb AB, et al. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2013 Oct;27(10):1252–1261.
   PubMed Web of Science ®Google Scholar
• Chiu HY, Chen CH, Wu MS, et al. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol. 2013 Dec;169(6):1295–1303.
   PubMed Web of Science ®Google Scholar
• Motaparthi K, Stanisic V, Van Voorhees AS, et al. From the medical board of the national psoriasis foundation: recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. J Am Acad Dermatol. 2014 Jan;70(1):178–186.
   PubMed Web of Science ®Google Scholar
• Billich A. Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency. IDrugs. 2007 Jan;10(1):53–59.
   PubMed Web of Science ®Google Scholar
• Cai X, Xu Y, Cheung AK, et al. PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling. Chem Biol. 2013 Jul 25;20(7):912–921.
   PubMed Web of Science ®Google Scholar
• Wada Y, Cardinale I, Khatcherian A, et al. Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis. PLoS One. 2012;7(4):e35069.
   PubMed Web of Science ®Google Scholar
• Burakoff R, Barish CF, Riff D, et al. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn’s disease. Inflamm Bowel Dis. 2006 Jul;12(7):558–565.
   PubMed Web of Science ®Google Scholar
• Ngiow SF, Teng MW, Smyth MJ. A balance of interleukin-12 and -23 in cancer. Trends Immunol. 2013 Nov;34(11):548–555.
   PubMed Web of Science ®Google Scholar
• Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013 Apr;168(4):844–854.
   PubMed Web of Science ®Google Scholar
• Wang K, Karin M. The IL-23 to IL-17 cascade inflammation-related cancers. Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 92):S87–90.
   PubMed Web of Science ®Google Scholar
• Mangan PR, Su LJ, Jenny V, et al. Dual inhibition of interleukin-23 and interleukin-17 offers superior efficacy in mouse models of autoimmunity. J Pharmacol Exp Ther. 2015 Aug;354(2):152–165.
   PubMed Web of Science ®Google Scholar
• Yonezawa A, Ohori M, Sasaki T, et al., inventors; Novel anti-human IL-23 receptor antibody. patent US20150126713. 2015.
   Google Scholar
• Bhandari A, Cheng X, Bourne G, et al. P-148 discovery of novel oral peptide antagonists of IL-23 receptor that are efficacious in a rat model of IBD. Inflamm Bowel Dis. 2016;22:S55.
   PubMed Web of Science ®Google Scholar
• Urech D Reprograming the tumor microenvironment from support to fight. PEGS; 2016; Boston.
   Google Scholar
• Urech D, Gunde T, Meyer S, inventors; Depletion of IL23R expressing cells in the treatment of various diseases. patent US20150329637. 2015.
   Google Scholar
• Schalper KA, Brown J, Carvajal-Hausdorf D, et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst. 2015;107(3). pii: dju435. doi:10.1093/jnci/dju435.
   Google Scholar
• O’Callaghan DS, Rexhepaj E, Gately K, et al. Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer. Eur Respir J. 2015 Dec;46(6):1762–1772.
   PubMed Web of Science ®Google Scholar
• Dirican N, Karakaya YA, Gunes S, et al. Association of intratumoral tumor infiltrating lymphocytes and neutrophil-to- lymphocyte ratio are an independent prognostic factor in non-small cell lung cancer. Clin Respir J. 2015 Nov 30. doi:10.1111/crj.12417. [Epub ahead of print].
   PubMedGoogle Scholar
• Walker JG, Ahern MJ, Coleman M, et al. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis. 2006 Feb;65(2):149–156.
   PubMed Web of Science ®Google Scholar
• Deisseroth A, Kaminskas E, Grillo J, et al. U.S. food and drug administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res. 2012 Jun 15;18(12):3212–3217.
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Uppal N, Wagner SA, et al. Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol. 2015 Dec 1;33(34):4039–4047.
   PubMed Web of Science ®Google Scholar
• Looyenga BD, Hutchings D, Cherni I, et al. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS One. 2012;7(2):e30820.
   PubMed Web of Science ®Google Scholar
• Thomas S, Fisher K, Snowden J, et al. Effect of methotrexate on JAK/STAT pathway activation in myeloproliferative neoplasms. Lancet. 2015 Feb 26;385(Suppl 1):S98.
   PubMedGoogle Scholar
• Curtis JR, Lee EB, Kaplan IV, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis. 2016;75(5):831–841.
   Web of Science ®Google Scholar
• Vignola AM. PDE4 inhibitors in COPD–a more selective approach to treatment. Respir Med. 2004 Jun;98(6):495–503.
   PubMed Web of Science ®Google Scholar
• Kolosionek E, Savai R, Ghofrani HA, et al. Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition: the role of phosphodiesterase 4. Mol Biol Cell. 2009 Nov;20(22):4751–4765.
   PubMed Web of Science ®Google Scholar
• Pullamsetti SS, Banat GA, Schmall A, et al. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF. Oncogene. 2013 Feb 28;32(9):1121–1134.
   PubMed Web of Science ®Google Scholar
• Karachaliou N, Codony-Servat J, Teixido C, et al. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. Sci Rep. 2015;5:17499.
   PubMed Web of Science ®Google Scholar
• Beutner KR AN2728 Clinical Data in Psoriasis, Online Source. 2012.
   Google Scholar
• Ross SE, Williams RO, Mason LJ, et al. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol. 1997 Dec 15;159(12):6253–6259.
   PubMed Web of Science ®Google Scholar
• Yeo CD, Kim JW, Ha JH, et al. Chemopreventive effect of phosphodieasterase-4 inhibition in benzo(a)pyrene-induced murine lung cancer model. Exp Lung Res. 2014 Dec;40(10):500–506.
   PubMed Web of Science ®Google Scholar
• Organtzis J, Lampaki S, Zarogoulidis P, et al. Phosphodiesterase (PDE)-4 inhibitors and COPD correlation with cancer. J Cancer. 2014;5(8):625–627.
   PubMed Web of Science ®Google Scholar
• Ohba F, Nomoto M, Hojo S, et al. Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis. J Dermatolog Treat. 2016 Jun;27(3):241–246.
   PubMed Web of Science ®Google Scholar
• Kubota S, Watanabe M, Shirato M, et al. An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice. Eur J Pharmacol. 2015 Dec 5;768:41–48.
   PubMed Web of Science ®Google Scholar
• Ciofani M, Madar A, Galan C, et al. A validated regulatory network for Th17 cell specification. Cell. 2012 Oct 12;151(2):289–303.
   PubMed Web of Science ®Google Scholar
• Kumar N, Lyda B, Chang MR, et al. Identification of SR2211: a potent synthetic RORgamma-selective modulator. ACS Chem Biol. 2012 Apr 20;7(4):672–677.
   PubMed Web of Science ®Google Scholar
• Kojima H, Muromoto R, Takahashi M, et al. Inhibitory effects of azole-type fungicides on interleukin-17 gene expression via retinoic acid receptor-related orphan receptors alpha and gamma. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):338–345.
   PubMed Web of Science ®Google Scholar
• Xu T, Wang X, Zhong B, et al. Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of RORgamma t protein. J Biol Chem. 2011 Jul 1;286(26):22707–22710.
   PubMed Web of Science ®Google Scholar
• Isono F, Fujita-Sato S, Ito S. Inhibiting RORgammat/Th17 axis for autoimmune disorders. Drug Discov Today. 2014 Aug;19(8):1205–1211.
   PubMed Web of Science ®Google Scholar
• Gege C. Retinoid-related orphan receptor gamma t (RORgammat) inhibitors from vitae pharmaceuticals (WO2015116904) and structure proposal for their Phase I candidate VTP-43742. Expert Opin Ther Pat. 2016 Mar;4:1–8.
   Google Scholar
• Cho ML, Ju JH, Kim KW, et al. Cyclosporine A inhibits IL-15-induced IL-17 production in CD4+ T cells via down-regulation of PI3K/Akt and NF-kappaB. Immunol Lett. 2007 Jan 15;108(1):88–96.
   PubMed Web of Science ®Google Scholar
• Wang K, Shi L, Yu Z, et al. Cyclosporine a suppresses the activation of the Th17 cells in patients with primary Sjogren’s syndrome. Iran J Allergy Asthma Immunol. 2015 Apr;14(2):198–207.
   PubMed Web of Science ®Google Scholar
• Kamata M, Tada Y, Tatsuta A, et al. Ciclosporin A inhibits production of interleukin-12/23p40 and interleukin-23 by the human monocyte cell line, THP-1. Clin Exp Dermatol. 2013 Jul;38(5):545–548.
   PubMed Web of Science ®Google Scholar
• Sato M, Tsujino I, Fukunaga M, et al. Cyclosporine A induces apoptosis of human lung adenocarcinoma cells via caspase-dependent pathway. Anticancer Res. 2011 Jun;31(6):2129–2134.
   PubMed Web of Science ®Google Scholar
• Liu T, Dai W, Li C, et al. Baicalin alleviates silica-induced lung inflammation and fibrosis by inhibiting the Th17 response in C57BL/6 mice. J Nat Prod. 2015 Dec 24;78(12):3049–3057.
   PubMed Web of Science ®Google Scholar
• Geisel J, Bruck J, Glocova I, et al. Sulforaphane protects from T cell-mediated autoimmune disease by inhibition of IL-23 and IL-12 in dendritic cells. J Immunol. 2014 Apr 15;192(8):3530–3539.
   PubMed Web of Science ®Google Scholar
• Kanakasabai S, Casalini E, Walline CC, et al. Differential regulation of CD4(+) T helper cell responses by curcumin in experimental autoimmune encephalomyelitis. J Nutr Biochem. 2012 Nov;23(11):1498–1507.
   PubMed Web of Science ®Google Scholar
• Lim SM, Jeong JJ, Choi HS, et al. Mangiferin corrects the imbalance of Th17/Treg cells in mice with TNBS-induced colitis. Int Immunopharmacol. 2016;34:220–228.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Apr;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005 Apr;5(4):263–274.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Xiao X, Wu Y, et al. Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients. Eur J Immunol. 2011 Aug;41(8):2314–2322.
   PubMed Web of Science ®Google Scholar
• Hirahara K, Ghoreschi K, Yang XP, et al. Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity. 2012 Jun 29;36(6):1017–1030.
   PubMed Web of Science ®Google Scholar
• Munir S, Andersen GH, Svane IM, et al. The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4 T cells. Oncoimmunology. 2013 Apr 1;2(4):e23991.
   PubMed Web of Science ®Google Scholar
• D’Addio F, Riella LV, Mfarrej BG, et al. The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J Immunol. 2011 Nov 1;187(9):4530–4541.
   PubMed Web of Science ®Google Scholar
• Dulos J, Carven GJ, van Boxtel SJ, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother. 2012 Feb-Mar;35(2):169–178.
   PubMed Web of Science ®Google Scholar
• Rui Y, Honjo T, Chikuma S. Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response. Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16073–16078.
   PubMed Web of Science ®Google Scholar
• Bandaru A, Devalraju KP, Paidipally P, et al. Phosphorylated STAT3 and PD-1 regulate IL-17 production and IL-23 receptor expression in Mycobacterium tuberculosis infection. Eur J Immunol. 2014 Jul;44(7):2013–2024.
   PubMed Web of Science ®Google Scholar
• Kopp T, Riedl E, Bangert C, et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature. 2015 May 14;521(7551):222–226.
   PubMed Web of Science ®Google Scholar
• Zandvliet A, Glasgow S, Horowitz A, et al. Tildrakizumab, a novel anti-IL-23 monoclonal antibody, is unaffected by ethnic variability in Caucasian, Chinese, and Japanese subjects. Int J Clin Pharmacol Ther. 2015 Feb;53(2):139–146.
   PubMed Web of Science ®Google Scholar